Chimeric Therapeutics Limited
CHMMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.25M
Close$
$0.00
97.3% downside
Current Fair Value
97.3% downsideOvervalued by 97.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.25 Million |
|---|---|
| Enterprise Value | $1.13 Million |
| Earnings per Share | $-0.61 |
| Beta | 0.74 |
| Outstanding Shares | 12,526,000 |
Return
| Return on Equity | 329.59% |
|---|---|
| Return on Assets | -1990.52% |
| Return on Invested Capital | 212.17% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.1 |
| Enterprise Value to Revenue | 0.12 |
| Enterprise Value to EBIT | -0.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.6 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 26, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Chimeric Therapeutics Limited
3 employees
CEO: Rebecca McQualter
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platfor...